The Role of ApoE4 in The Acceleration of Tau Aggregation

Abstract Background Understanding modulators of Alzheimer's disease’s (AD) progression is crucial for determining optimal treatment windows and targets. Apolipoprotein E e4 (ApoE4), i.e. a key AD risk factor, is associated with earlier tau accumulation at lower Aß levels (Steward et al. 2023), yet, the mechanisms driving this connection remain unclear. Thus, we assessed whether ApoE4 accelerates initial Aß‐related tau secretion measurable in CSF or subsequent tau aggregation as determined via PET (Figure 1A). Method We combined cross‐sectional CSF measures of phosphorylated tau (p‐tau181) and Aß‐PET in 287 APOE genotyped non‐demented (cognitively normal [CN]; mildly cognitively impaired [MCI]) ADNI participants. P‐tau181 was adjusted to Aß40 to account for inter‐individual variability in CSF protein concentrations. Using linear regression, we investigated i) whether ApoE4 was related to accelerated Aß‐related p‐tau secretion (i.e., Aß‐PET by ApoE4 interaction on p‐tau181), ii) whether ApoE4 accelerated the p‐tau‐induced fibrillisation of tau (i.e. p‐tau181 by ApoE4 interaction on tau‐PET) and iii) whether regional effects of ApoE4 on p‐tau‐related tau fibrillisation were associated with ApoE4 mRNA expression levels. Result ApoE4 did not moderate the relationship between Aß‐PET and p‐tau181 (Figure 1B, p=0.76) but strengthened the effect of p‐tau181 on global Tau‐PET increase (Figure 1C, ß=0.7, p<0.001). At the regional level, this ApoE4 x p‐tau181 interaction on tau‐PET was correlated with regional APOE mRNA expression in CN (Figure 2B, r=0.5, pspin<0.001), but not in MCI (p=0.141), suggesting that ApoE4 drives earliest p‐tau‐induced tau aggregation. Supporting this further, we found that the regional effect of p‐tau181 on Tau‐PET was more strongly correlated with APOE mRNA expression in CN ApoE4 carriers (Figure 2C, r=0.54, pspin<0.001) than in CN non‐carriers (r=0.4, pspin=0.05). Lastly, we confirmed that the effect of Aß on tau aggregation is mediated by p‐tau increases (Figure 1D, ACME: B=0.28; p<0.001; ADE: B=0.206; p=0.008) which is strengthened in ApoE4 carriers (B=0.21, p=0.006). Conclusion ApoE4 promotes p‐tau‐induced tau aggregation, particularly in early disease stages and in regions that express high APOE. This suggests that ApoE4 can trigger earlier Aß‐related tau spreading most likely due to facilitated p‐tau induced tau aggregation. This suggests that preventing soluble p‐tau increases may attenuate tau aggregation and therefore dementia.